Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Net Margin (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Net Margin for 11 consecutive years, with 541.65% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 37322.0% year-over-year to 541.65%, compared with a TTM value of 767.51% through Dec 2025, down 260013.0%, and an annual FY2025 reading of 764.01%, down 260994.0% over the prior year.
  • Net Margin was 541.65% for Q4 2025 at Agios Pharmaceuticals, up from 803.05% in the prior quarter.
  • Across five years, Net Margin topped out at 10574.69% in Q3 2024 and bottomed at 1471.24% in Q1 2023.
  • Average Net Margin over 3 years is 94.11%, with a median of 1026.7% recorded in 2025.
  • The sharpest move saw Net Margin soared 1180896bps in 2024, then plummeted -1137774bps in 2025.
  • Year by year, Net Margin stood at 1374.81% in 2023, then soared by 33bps to 914.87% in 2024, then surged by 41bps to 541.65% in 2025.
  • Business Quant data shows Net Margin for AGIO at 541.65% in Q4 2025, 803.05% in Q3 2025, and 903.6% in Q2 2025.